China-based CanSino Biologics (SHA: 688185, HKG: 6185) has entered into a strategic partnership with Indonesia-based PT Etana Biotechnologies (Etana) to focus on the research and development of inhaled tuberculosis vaccines. The collaboration aims to leverage both companies’ expertise to advance novel vaccination methods against tuberculosis, although no financial details of the agreement have been disclosed.
Focus on Innovative Tuberculosis Vaccines
The partnership between CanSino Biologics and Etana underscores a shared commitment to addressing the global health challenge posed by tuberculosis. By focusing on inhaled vaccines, the companies aim to develop a more patient-friendly and potentially more effective method of vaccination against the disease.
Combining Expertise for Global Health Impact
This collaboration brings together CanSino Biologics’ experience in biologics development with Etana’s regional expertise and manufacturing capabilities. The joint effort is expected to contribute to the global fight against tuberculosis by providing innovative solutions to the diagnosis, prevention, and treatment of the disease.-Fineline Info & Tech
